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fractionation schedules. When 2 Gy equivalent doses to the rectum or 
bladder (EQD2 assuming rectal/bladder a/b=3) were compared 
between those suffering from Gr 2 toxicity or less, we found absolute 
dose-volumes to be better predictors than relative dose-volumes. 
Those with Gr 2 GI toxicity had a significantly higher V50GyEQD2 (29.7cc 
vs. 17.8cc, p=0.01) and V60GyEQD2 (27.6cc vs. 18.4cc, p=0.04). Higher 
dose volumes were not different. Those with Gr 2 GU toxicity had a 
significantly higher V70GyEQD2 (36.6cc vs. 18.7cc, p=0.004) and 
V65GyEQD2 (36.8cc vs. 19.0cc, p =0.004). ROC curve analysis showed 
that V50GyEQD2> 17.3cc and V60GyEQD2 > 9.8cc were best thresholds for 
Gr 2 GI toxicity.Reliable threshold estimates were not obtained for GU 
toxicity due to small numbers with Gr 2 toxicity. 
Conclusions: Moderate hypofractionation with IG-IMRT is well-
tolerated, even with elective pelvic irradiation. Dosimetric 
correlations indicate that certain absolute dose-volume parameters 
may be useful in predicting acute toxicity with these fractionation 
schedules. 
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Purpose/Objective: Adjuvant radiotherapy after prostatectomy for 
prostate cancer has not increased enough compared to salvage 
radiotherapy in Japan. We retrospectively evaluated the outcome in 
patients receiving adjuvant radiotherapy and prognostic factors in 
Japan.  
Materials and Methods: Between 2005 and 2008, a total of 91 patients 
were referred for adjuvant radiotherapy in 23 institutions. Median 
age: 64 years (53-78 years), Median i-PSA: 11.8ng/ml (4.8-280ng/ml). 
Gleason score (GS):6 /7 /8 /9 /10 =6.6% / 37.8%/ 22.2%/ 26.7%/0%. 
Positive rates of marginal status, seminal vesicle invasion (SVI) and 
Extra-prostatic extension (EPE) were 73.3%, 28.9%, 65.6%, 
respectively. Median postoperative PSA nadir: 0.18ng/ml 
(0~2.51ng/ml). Median time from surgery to radiotherapy was 3 
months (1~12 months). A total dose of 60-65Gy was administered in 
65.6% of patients. 
Results: Median follow-up was 62 months. The 3- and 5-years bRFS 
rate for all patients were 65.6% and 56.5%, respectively. A statistically 
significant relationship existed between GS and marginal status 
(p=0.019), GS and SV (p=0.001), marginal status and EPE (p=0.017), 
type of hormonal therapy and total dose (p=0.026). The 5-year bRFS in 
patients with SV negative was 65.1% compared to 35.8% with SV 
positive (p=0.001). The 5-year bRFS in postoperative PSA nadir?0.2 
was significantly higher than postoperative PSA nadir>0.2 (68.3% vs. 
43.6%, p=0.02). The 5-year bRFS in patients who were given 
radiotherapy ?3 months from surgery tended to be more favorable 
than >3 months (p=0.069). On multivariate analysis, SV invasion and 
postoperative PSA nadir were independent prognostic factors for a 
reduced bRFS (p=0.001 and 0.018, respectively). Age, i-PSA, GS, 
marginal status, EPE, hormonal therapy and total dose were no longer 
an independent prognostic factors. 
Conclusions: The 3- and 5-years bRFS rate for all patients were 65.6% 
and 56.5%, respectively. SV invasion and postoperative PSA nadir were 
most significant prognostic factors.  
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Purpose/Objective: Cone beam CT (CBCT) images can be captured 
during delivery of VMAT rotational radiotherapy. The quality of 
simultaneous CBCT’s is affected by scatter from the megavoltage 
beam and artefact from other factors such as bowel gas. We 
developed, verified and used a novel scoring system to rate the 
quality and clinical usefulness of simultaneous CBCT’s captured during 
prostate radiotherapy. 
Materials and Methods: A novel three point scoring system was 
developed to score the quality of CBCT scans; this reflected whether 
CBCT’s were of sufficient quality to be used in clinical practice to 
verify the position of the prostate. Two oncologists and three 
radiographers each scored 25 CBCT’s in order to validate the scoring 
system. To assess intra-observer variability, each observer re-scored 5 
of the previously assessed CBCT’s. Fifteen patients with localised 
prostate cancer were treated with radical VMAT radiotherapy. 
Treatment was delivered using a single 8 MV arc on an Elekta linear 
accelerator fitted with a Synergy CBCT system. Standard and 
simultaneous CBCT’s were captured on fractions 1, 6, 11 and 16. The 
simultaneous CBCT data was reconstructed and image quality was 
improved using in-house software. Using the validated scoring system, 
2 observers scored 120 CBCT’s collected during treatment of the 15 
patients; 60 scans were standard CBCT’s and 60 were corrected 
simultaneous CBCT’s (csCBCT). 
Results: During the validation exercise, inter-observer variability was 
low; Fleiss’ kappa statistic 0.796. There was greatest agreement 
regarding the best quality scans; kappa statistic 0.910. Intra-observer 
variability was also low; mean kappa statistic 0.82 (range 0.67-1.00).  
During the second scoring exercise, observer 1 rated 60 (100%) 
standard CBCT’s and 40 (67%) csCBCT’s to be clinically useful. 
Observer 2 rated 58 (97%) standard CBCT’s and 49 (82%) csCBCT’s to 
be clinically useful. The two observers agreed that 36 (60%) csCBCT’s 
were of sufficient quality to be useful for clinical decision making. 
Further results of how each observer rated the quality of the CBCT’s 
are given in table 1. 
 
 Observer 1 Observer 2 
Standard 
CBCT 
csCBCT Standard 
CBCT 
csCBCT 
Low quality CBCT
(Not clinically useful) 
0 20 
(33%) 
2 (3%) 11 
(18%) 
Intermediate quality
CBCT 
(Clinically useful) 
25 (42%) 37 
(62%) 
14 (23%) 45 
(75%) 
Good quality CBCT
(Clinically useful) 
35 (58%) 3 (5%) 44 (73%) 4 (7%) 
 
Table 1. Results of scoring exercise for 60 standard CBCT's and 60 
corrected simultaneous CBCT's (csCBCT) 
Conclusions: Simultaneous CBCT identifies the position of the 
prostate during treatment delivery and removes the uncertainty of 
prostate motion in the interval between standard CBCT and 
treatment. This provides a more accurate assessment of target 
coverage during treatment. Simultaneous scanning also reduces the 
time the patient is on the treatment couch. The quality of 
simultaneous CBCT’s is degraded by megavoltage scatter and artefact. 
Despite this, simultaneous CBCT scanning can produce images which 
are of sufficient quality to be used for clinical decision making. 
Further development and refinement of this technique is warranted. 
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Purpose/Objective: Some patients with localised prostate cancer 
treated with SBRT have been noted to experience short-lived but 
troublesome genitourinary symptoms consisting of frequency and 
dysuria associated with a marked rise in the International Prostate 
Symptom Score (IPSS). Gastrointestinal symptoms have not been 
frequent. We investigated potential patient specific and dosimetric 
parameters that may predict for this syndrome and to suggest 
selection criteria that may reduce the incidence.  
Materials and Methods: Eighteen consecutive patients undergoing 
prostate SBRT at our institution for organ-confined prostate cancer 
had IPSS toxicity recorded at baseline and then every 2 weeks for 12 
weeks after the commencement of SBRT. The maximal recorded IPSS 
was tested against various patient parameters (prostate volume, 
bladder volume and separation at the level of the prostate) and 
features of the radiotherapy plan including bladder and urethral DVH 
parameters used in clinical practice. Patients were not catheterised 
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but the position of the urethra was seen on some MRI slices and 
extrapolated on others. Prophylactic alpha-blockers were not given.  
Results: Six patients experienced urinary symptoms resulting in an 
IPSS rise of 14 points or more. Maximal IPSS scores during the follow-
up period ranged from 4-35. Mean DVH parameters are shown in the 
table below.  
 
  
A significant correlation was found between the volume of urethra 
receiving 40 Gy (P=0.011) and 42 Gy (P=0.0006) and the maximum IPSS 
after prostate SBRT. This association remains highly significant 
(P=0.002) even when adjusted for the baseline IPSS. Patients with a 
V42 Gy below the mean value (47%) rarely experienced toxicity (2/11 
patients) compared with a V42 Gy>47% where 4/7 had a significant 
IPSS rise. The dose to 10% of the bladder was also correlated with 
maximal IPSS score (P=0.039).  Volume of urethra receiving 45.6 Gy 
was often 0% and was not correlated with IPSS. For the other bladder 
parameters tested (D40%, dose to hottest 10cc and 3cc) no significant 
correlation was observed in this series. Bladder and prostate volume 
did not predict for symptoms and neither did the IPSS score at 
baseline.  
Conclusions: Prediction of those who will experience acute GU 
symptoms after prostate SBRT is difficult but appears highly 
correlated with dose to the urethra. We suggest that keeping the 
urethral V42Gy <47% may reduce acute urinary morbidity or where this 
is not possible, the utility of prophylactic alpha-blockers could be 
examined.  
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Purpose/Objective: To quantify inter-/intrafraction prostate motion 
and patient setup variation by using kV cone beam CT (CBCT) scans 
during the course of prostate RapidArc therapy.  
Materials and Methods: 1288 weekly CBCT scans were obtained on 
161 patients with prostate cancer [MRI stages:T1-2%, T2-22%, T3a-
11%, T3b 65%] undergoing high- dose RapidArc therapy (mean total 
dose: 81.1Gy). Additionally, 528 weekly post-treatment CBCT scans of 
66 of these patients were acquired. The CBCT scans were 
superimposed on the Planning-CT scans by using the Eclipse automatic 
registration and match algorithm of the EclipseTM planning module 
version (VARIS Vision 8.6.07). Inter-/intrafraction motion defined by 
CBCT consists of two components: the prostate movement and the 
patient setup displacement. Deviations were measured in 
anteroposterior (AP), right- left (RL), and superior- inferior (SI) 
directions, as well as rotation angles around the AP axis relative to 
the isocenter. 
Results: The interfraction motion was most significant in AP direction, 
followed by SI and RL directions. The mean prostate deviation (mean± 
SD) was 1.7mm ± 1.5mm (max.:15 mm), 1.5mm ± 1.4mm (max.: 
11mm) and 0.9mm ± 0.8 mm (max.: 7mm) in the AP and SI and RL 
directions, respectively. The mean interfraction rotation was 
0.8°±0.6°(max.:4.7°) around the AP axis. The intrafraction motion 
was significantly smaller; the mean intrafraction displacements were 
0.8mm ± 0.7 mm (max.: 6 mm), 0.7mm ± 0.6mm (max.:4 mm), and 
0.9mm ± 0.7mm (max.:6 mm) in AP, SI and RL directions, 
respectively. The mean intrafraction rotation was 0.5°±0.5° 
(max.:4.7°) around the AP axis. The frequency of interfraction motion 
was more than 4mm in 5.2%, 5%, 0.7% and more than 5mm in 2.3%, 
2.3%, 0.2% of patients in AP, SI and RL directions, respectively. An 
intrafraction displacement of more than 2mm occurred in 3.5%, 1.2%, 
4.2% and more than 3mm in 0.8%,0.2%, 1.5% of measurements in AP, 
SI and RL directions, respectively. The frequency of inter-
/intrafraction rotation was >2° in 11.6% / 4.2%, > 2.5° in 6.8% / 3% 
and > 3° in 2.7% / 1.7% of patients, respectively. 
Conclusions: Our findings suggest that the interfraction motion was 
small and occurred predominantly in AP direction. In contrast, the 
intrafraction variability seems to be clinically insignificant. The use of 
cone-beam-CT guided RapidArc allows both an accurate prostate 
localization and shorter treatment times for dose-escalated 
irradiation, thus enabling significant margin reduction.  
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Purpose/Objective: With the development of real time tracking 
technologies we have the capabilities to conform radiotherapy 
directly to the target before (inter-fraction) and during (intra-
fraction) treatment delivery providing accurate and effective 
targeting , allowing us to respond and adapt accordingly. The Calypso 
™ tracking system is used to localise and track the prostate. This 
system has been clinical at the proposed site since January 2010 and 
to date has effectively treated more than 30 patients. 
Materials and Methods: Calypso ™ is a motion management system 
that involves inserting 3 Beacon electromagnetic transponders into the 
prostate. The systems array excites these transponders causing them 
to emit radiofrequency signals, it receives and uses these signals to 
map their exact location. This information gets sent to the tracking 
station which verifies treatment isocentre and tracks the movement 
of the transponders during treatment delivery. To improve treatment 
delivery we conducted a study to determine new planning target 
volume margins for prostate patients' implanted with fiducial markers 
and those implanted with electromagnetic transponders. We used the 
Calypso™ data from the first 20 prostate patients who we localised 
using 3 skin marker tattoos followed by transponder detection and 
auto couch repositioning. Intra-fraction organ motion was monitored 
continuously using the Calypso™ system recording sub-millimetre 
motion throughout. 
Results: A total of 740 fractions were analysed and recommendations 
for new margins calculated using van Herks formula. The margins for 
fiducial marker patients are predictably greater than those of the 
transponder tracking, this takes into account we are unable to correct 
for intra-fraction motion on the fiducial group. The margin values are 
currently being verified by an independent statistician to ensure 
accuracy of calculation, formula use and the recommended 
guidelines. 
Conclusions: Localisation and intra-fraction tracking with Calypso™ 
and fiducial localisation allows a marked reduction in PTV margins. 
Although fiducial localisation margins cannot be as tight due to the 
intra-fractional prostate motion being a limiting factor. Applying 
these new margins will undoubtedly reduce normal tissue toxicity and 
side effects commonly …..by this group of patients. 
Limitations: The transponders cause voids on MRI follow up scans, 
tracking system cannot be used in conjunction with artificial hips 
/metal prosthesis around the pelvic area. 
Future: Once the new margins are implemented outcomes data will 
be collected. Aim to utilise the Calypso tracking™ system on other 
areas of the body. Study proposal in the use of transponders in the 
pancreas in line with University Hospital of Pennsylvania 13 
   
 
 
 
 
 
  
  
  
  
 
